Propiverine modified-release formulation (Mictoryl, MR) and propiverine pediatric (Mictoryl Pediatric) are detrusor relaxant drugs with antimuscarinic and calcium-modulating properties indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). Propiverine MR is available in 30 mg and 45 mg capsules, taken once daily, for adults with OAB. Propiverine pediatric is an immediate-release formulation (IR) available in 5 mg tablets for children, with body weight–adjusted dosage to be taken twice daily. The manufacturer has submitted a price of $1.39 per 30 mg or 45 mg MR capsule ($1.39 per day), and $0.37 per 5 mg IR tablet ($0.74 to $2.22 per day). Propiverine IR 15 mg was never marketed in Canada.

Contents

• Abbreviations
• Executive Summary
  • Background
  • Summary of the Economic Analysis Submitted by the Manufacturer
  • Key Limitations
  • Issues for Consideration
  • Results/Conclusions
  • Cost Comparison Table
• APPENDIX 1. Reviewer Worksheets
• References

The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The statements, findings, conclusions, views, and opinions contained and expressed in this publication are based in part on data obtained under licence from QuintilesIMS Inc. concerning the following information services: PharmaStat and DeltaPA. All Rights Reserved. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party data supplier.